Imafuku S, Tada Y, Hippeli L, Banerjee S, et al. Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial. J Dermatol 2023 Mar 7. doi: 10.1111/1346-8138.16740.
PMID: 36882942